TONIX Pharmaceuticals, Inc.' Bedtime Very Low Dose Cyclobenzaprine Study Featured in Journal of Rheumatology

NEW YORK--(BUSINESS WIRE)--TONIX Pharmaceuticals, Inc. a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”), including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder, announces the publication of data in the peer-reviewed journal, The Journal of Rheumatology, demonstrating an improvement in core symptoms associated with FM.

Back to news